Changzhou Wuhe Biopharmaceutical

Changzhou Wuhe Biopharmaceutical is a specialty pharmaceutical company based in Changzhou, China, that focuses on the development of complex generic drugs and advanced drug delivery systems. The company specializes in liposomal formulations, with its lead product, Doxorubicin Hydrochloride Liposomal, receiving regulatory approval in China in 2024 for various oncology indications. Beyond its commercial portfolio, Changzhou Wuhe is actively developing innovative delivery technologies, such as multivesicular liposomes, to enhance the therapeutic profile of existing drugs in areas like pain management. The company leverages its expertise in lipid-based chemistry and formulation science to address unmet clinical needs through improved drug stability and targeted delivery.